Adimmune Corporation AI Stock Analysis
Adimmune Corporation (4142) AI Stock Analysis
Adimmune Corporation
(TWSE:4142)
The score is low primarily because of deteriorating financial performance: three straight years of revenue decline and net losses, halved gross margins, and a return to negative free cash flow in 2025. Technicals reinforce the caution, with the share price below all major moving averages and a negative MACD, although extremely low RSI and Stochastic readings suggest the selling may be stretched in the near term. Valuation offers no support given negative earnings and no dividend. The main mitigating factor is a still-reasonable balance sheet, with equity funding about 60% of assets and moderate leverage, which gives the company time to attempt a turnaround. Investors should watch for revenue stabilization and a return to positive free cash flow as evidence of an inflection.
Adimmune Corporation (4142) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 7.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 994.87K
- Price to Earnings (P/E)
- -48.7
- Beta (1Y)
- 0.47
- Revenue Growth
- 34.06%
- EPS Growth
- ―
- Country
- TW
- Employees
- 564
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Adimmune Corporation Business Overview & Revenue Model
Company Description
Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influen...
Adimmune Corporation Financial Statement Overview
Summary
Fundamentals are weak and still deteriorating. Revenue has declined three years in a row (from about NT$2.25bn in 2022 to NT$1.40bn in 2025), gross margin has halved to 20.6%, and the company has booked three consecutive years of operating and net losses. Cash flow is erratic: after a solid 2024 rebound, 2025 returned to roughly breakeven operating cash flow and negative free cash flow of -NT$242m. The balance sheet is the one offset, with equity funding about 60% of assets and debt-to-equity of 0.57x providing staying power, though equity has eroded every year since 2020 while total debt has more than doubled.
Income Statement
24NegativeBalance Sheet
55NeutralCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.40B | 1.56B | 1.79B | 2.25B | 1.64B |
| Gross Profit | 306.32M | 288.49M | 448.06M | 410.94M | 891.08M | 464.14M |
| EBITDA | -40.87M | -144.69M | -84.30M | -512.43M | 438.12M | 254.89M |
| Net Income | -233.50M | -239.89M | -242.75M | -639.89M | 290.98M | 43.07M |
Balance Sheet | ||||||
| Total Assets | 8.11B | 8.19B | 8.48B | 9.48B | 9.15B | 8.01B |
| Cash, Cash Equivalents and Short-Term Investments | 1.82B | 2.24B | 2.47B | 2.49B | 2.97B | 2.89B |
| Total Debt | 3.03B | 2.83B | 2.60B | 3.14B | 2.26B | 1.32B |
| Total Liabilities | 3.41B | 3.14B | 2.92B | 3.71B | 2.60B | 1.58B |
| Stockholders Equity | 4.62B | 4.94B | 5.23B | 5.47B | 6.12B | 6.15B |
Cash Flow | ||||||
| Free Cash Flow | -264.41M | -242.18M | 513.26M | -1.11B | -711.59M | -1.33B |
| Operating Cash Flow | -64.25M | -5.45M | 668.48M | -892.35M | -291.96M | -480.52M |
| Investing Cash Flow | -171.79M | -198.98M | -310.90M | -366.56M | -322.07M | -728.84M |
| Financing Cash Flow | 147.63M | 56.19M | -478.80M | 859.30M | 823.19M | -222.89M |
Adimmune Corporation Peers Comparison
Overall Rating
TW:416954Neutral
TW:417448Neutral
TW:412844Neutral
TW:654143Neutral- TW:414237Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4169 | 54Neutral | TWD 7.93B | -291.25 | ― | 0.27% | ― | ― |
| TW:4174 | 48Neutral | TWD 7.23B | -2.37 | ― | ― | -2.20% | 29.08% |
| TW:4128 | 44Neutral | TWD 7.85B | 24.61 | ― | ― | 4.85% | ― |
| TW:6541 | 43Neutral | TWD 7.47B | -5.03 | -26.61% | ― | 207.37% | 4.17% |
| TW:4142 | 37Underperform | TWD 7.22B | -48.68 | ― | ― | 34.06% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4142 | Adimmune Corporation | 16.60 | -3.00 | -15.31% | |
| TW:6541 | Tanvex Biopharma | 28.15 | -27.55 | -49.46% | |
| TW:4128 | Microbio Co., Ltd. | 13.45 | -7.35 | -35.34% | |
| TW:4169 | TCM Biotech International Corp. | 116.50 | -64.77 | -35.73% | |
| TW:4174 | OBI Pharma, Inc. | 60.50 | 11.70 | 23.98% | |
| TW:7876 | Obigen Pharma, Inc. | 66.20 | 29.51 | 80.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026